[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"leadSponsorName\":\"Nova Southeastern University\",\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:":498},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,18,0,[8,51,74,99,127,153,180,205,231,260,292,313,341,371,401,431,453,474],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":15,"eligibilityCriteria":16,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":30,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":39,"lastUpdatePostDateStruct":40,"startDateStruct":43,"completionDateStruct":45,"leadSponsor":47,"locationsCount":50},"100607348","investigating-the-impact-of-electrical-stimulation-on-facial-pain-jaw-movement-and-oral-health-in-people-with-motor-neuron-disease-100607348",false,"NCT07187388","Investigating the Impact of Electrical Stimulation on Facial Pain, Jaw Movement and Oral Health in People With Motor Neuron Disease.","The Impact of Transcutaneous Electrical Stimulation on Facial Pain, Jaw Mobility, and Oral Health in Individuals With Motor Neuron Disease.","MND","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited) OR diagnosis of definite PLS by the treating neurologist and based on the consensus diagnostic criteria for PLS\n* Subjective report of jaw pain, indicated by a NRS score of \\> or = 3\u002F10.\n\nExclusion Criteria:\n\n* history of head or neck cancer\n* history of CVA\n* history of past facial surgery with hardware placement\n* history of pacemaker\n* diagnosis of significant cognitive impairment by the treating physician\n* history of seizures or diagnosis of epilepsy\n* open wound at the area of electrode placement\n* complete loss of sensation at the area of electrode placement","ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this clinical trial is to evaluate the impact of non-invasive electrical stimulation, when placed on the facial muscles can reduce facial pain and improve jaw mobility, and chewing in individuals with Amyotrophic Lateral Sclerosis (ALS) and Primary Lateral Sclerosis (PLS). The secondary goal is to evaluate the impact of non-invasive electrical stimulation on patient reported difficulty performing oral hygiene tasks in individuals with ALS and PLS. Participants will attend one in-person clinic visit and participate in one telephone interview 24 hours after the treatment. The clinic visit will include pre-intervention assessments, a single 30-minute treatment of electrical stimulation followed by post-intervention assessments.\n\nThe assessments will include a self-rating of jaw and facial pain, a range of motion test where participants will be asked to open their jaw as wide and as far to the side as possible, and a chewing efficiency test using a saltine cracker. Twenty-four hours later, participants will receive a follow-up phone call to self-rate their facial pain and report any difficulty performing oral hygiene tasks.\n\nThe treatment consists of a single 30-minute electrical stimulation session. Electrode pads will be placed on the participant's facial region, specifically over the masseter muscle belly and the TMJ area, while the participant is seated comfortably. The pads will be connected to an FDA-approved electrical stimulator, and the current will be adjusted to the participant's comfort level. Once set, the participant will remain seated for 30 minutes. At the end of the session, the stimulator will be turned off and the electrode pads removed.",[27,28,29],"Amyotrophic Lateral Sclerosis (ALS)","Primary Lateral Sclerosis (PLS)","Motor Neuron Disease, Amyotrophic Lateral Sclerosis",[31,32,33,34,35,15,36,37],"Amyotrophic Lateral Sclerosis","Primary Lateral Sclerosis","ALS","PLS","Motor Neuron Disease","Facial Pain","jaw pain","RECRUITING","2026-05-22",{"date":41,"type":42},"2026-05-27","ACTUAL",{"date":44,"type":42},"2026-04-02",{"date":46,"type":21},"2026-08-13",{"name":48,"class":49},"Nova Southeastern University","OTHER",1,{"id":52,"slug":53,"hasResults":11,"nctId":54,"briefTitle":55,"officialTitle":55,"acronym":4,"eligibilityCriteria":56,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":58,"targetDuration":4,"studyType":22,"phases":60,"briefSummary":61,"conditions":62,"keywords":4,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":4},"100638430","transcutaneous-superior-laryngeal-nerve-stimulation-to-upregulate-swallowing-frequency-and-urge-to-swallow-in-patients-living-with-als-100638430","NCT07606235","Transcutaneous Superior Laryngeal Nerve Stimulation to Upregulate Swallowing Frequency and Urge to Swallow in Patients Living With ALS","Inclusion Criteria:\n\n* Confirmed diagnosis of ALS (El-Escorial Criteria)\n* ALS FRS Bulbar Subscore of ≤ 10 and ≥ 3.\n* Functional Oral Intake scale score ≥ 2\n\nExclusion Criteria:\n\n* A diagnosis of significant cognitive impairment or frontotemporal dementia per the treating neurologist or neuropsychologist,\n* Current nasogastric tube placement\n* Current head and neck carcinoma\n* Pacemaker or implanted defibrillator or history of diagnosed arrhythmia, bradycardia, or repeated attacks of hypotension,\n* Implanted vagal nerve stimulator\n* Current pregnancy\n* History of epilepsy\n* Infected, broken or inflamed skin on the neck, or impaired sensation at the site of sEMG or TENS placement\n* Living greater than 50 miles from the NSU clinic round trip\n* Any clinical reason that this stimulation may not be a suitable treatment according to the principal investigator.","90 Years",{"count":59,"type":21},5,[24],"Prospective, single-arm pilot study evaluating transcutaneous electrical nerve stimulation of the superior laryngeal nerve (TENS-SLN) in individuals with ALS.\n\nUp to 5 participants with confirmed ALS and bulbar involvement will be enrolled.\n\nPrimary outcomes: swallowing frequency and perceived urge to swallow. Participants complete a baseline visit, followed by two supervised treatment sessions within one week, and a final post-treatment evaluation.\n\nOptional visits (up to 2) may be used to individualize stimulation parameters prior to treatment.\n\nSwallowing function will be assessed using physiological monitoring, fiberoptic endoscopy, and videofluoroscopic swallow study (VFSS).\n\nTENS-SLN is a non-invasive neuromodulation approach targeting sensory pathways to facilitate swallowing without inducing muscle contraction.\n\nThis pilot study is designed to assess feasibility, safety, and preliminary effect sizes to inform future randomized trials, and is not powered to determine efficacy.",[27,63,64],"Dysphagia","Dystussia","NOT_YET_RECRUITING","2026-05-18",{"date":68,"type":42},"2026-05-26",{"date":70,"type":21},"2026-06",{"date":72,"type":21},"2026-12",{"name":48,"class":49},{"id":75,"slug":76,"hasResults":11,"nctId":77,"briefTitle":78,"officialTitle":79,"acronym":4,"eligibilityCriteria":80,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":81,"enrollmentInfo":82,"targetDuration":4,"studyType":22,"phases":84,"briefSummary":85,"conditions":86,"keywords":89,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":91,"lastUpdatePostDateStruct":92,"startDateStruct":94,"completionDateStruct":96,"leadSponsor":98,"locationsCount":50},"100615698","tongue-strengthening-exercises-in-people-with-als-100615698","NCT07295990","Tongue-strengthening Exercises in People With ALS.","The Impact of Dysphagia Exercise on Oropharyngeal Swallowing Function in Patients With ALS","Inclusion Criteria:\n\n* Diagnosis of possible, probable, or definite ALS (El-Escorial Revisited)\n* Lingual exercises naïve\n* Impaired lingual strength generation compared to normative data\n* EAT-10 score \\\u003C3\n\nExclusion Criteria:\n\n* Stroke\n* Head injury\n* Head and neck cancer\n* Tracheostomy\n* Other concomitant neurogenic disorder\n* Recent oral surgery other than routine dental surgery\n* Unable to generate isometric lingual pressure on lingual manometer\n* Participation in another clinical trial intervention that may confound results\n* NPO (nothing by mouth)\n* Anarthric","99 Years",{"count":83,"type":21},20,[24],"This study is testing a tongue exercise program for people living with ALS to see if it can help support speech and swallowing. All participants will receive the treatment, and researchers will measure changes over time by comparing each person's results to their own earlier results.\n\nPeople who join the study will have two in-person visits and four weekly telehealth sessions with a speech-language pathologist. During these sessions, participants will practice tongue resistance exercises, complete speech and swallowing tasks, and answer surveys about their experience. They will also use a small device at home to measure tongue strength and swallowing.\n\nThe exercise program involves pressing the tongue against a device several times a day, five days per week, for five weeks. Researchers want to learn if this program is safe, practical, and helpful for people with ALS.",[87,88],"ALS (Amyotrophic Lateral Sclerosis)","ALS - Amyotrophic Lateral Sclerosis",[33,31,63,90],"Dysarthria","2026-05-05",{"date":93,"type":42},"2026-05-11",{"date":95,"type":21},"2026-05-01",{"date":97,"type":21},"2029-01",{"name":48,"class":49},{"id":100,"slug":101,"hasResults":11,"nctId":102,"briefTitle":103,"officialTitle":104,"acronym":4,"eligibilityCriteria":105,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":107,"targetDuration":4,"studyType":22,"phases":109,"briefSummary":112,"conditions":113,"keywords":115,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":119,"lastUpdatePostDateStruct":120,"startDateStruct":122,"completionDateStruct":124,"leadSponsor":126,"locationsCount":50},"100473218","phase-1-rh-pdgf-vs-emd-for-treatment-of-intra-bony-defects-100473218","NCT05442034","Rh-PDGF vs EMD for Treatment of Intra-bony Defects","Rh-PDGF Versus Emdogain for Treatment of Intra-bony Defects","Inclusion Criteria:\n\n* Age is 18 years old and older\n* Absence of relevant medical conditions\n* Availability for 6-month follow-up\n* Subjects who recently have received scaling and root planing due to periodontal disease\n* Single-rooted and multi-rooted teeth in either the maxilla or the mandible.\n* Presence of interdental periodontal pocket with PD ≥ 6 mm associated to an intra-bony component ranged from 3 to 6 mm.\n* Non-contained intra-bony defects (1-wall, 2-wall intra-bony defects)\n* Full-mouth plaque score (FMPS) and full-mouth bleeding score (FMBS) \\\u003C20% at surgery\n\nExclusion Criteria:\n\n* Female patients who are pregnant or planning to be pregnant during the period of the study\n* Heavy smokers (\\>10 cigarettes a day)\n* Subjects not willing to comply to the study protocol\n* Patients with uncontrolled diabetes (HbA1c \\>7.5)\n* Patients receiving medications that may affect periodontal status in the previous 6 months (e.g., Phenytoin, Alendronate)\n* Periapical lesion in the tested sites",true,{"count":108,"type":21},36,[110,111],"PHASE1","PHASE2","Treatment of intra-bony defects is challenging and requires extensive knowledge of the etiology, anatomy, occlusion, and available biomaterials that can be used to treat this kind of defects. Patients who received scaling and root planing at the college of dental medicine due to periodontal disease, will be screened for inclusion. Only subjects who showed persistent deep probing depth associated with an intrabony defect will be included and will be randomly allocated to one of two treatment groups. One group will be treated using recombinant human platelet derived growth factor (GEM-21) (test) added to allogenic bone graft, second group will be treated using enamel matrix derivatives (EMD) (control) with allograft. Both groups will be treated using the same surgical protocol. Patients will be followed up for a period of 6 months and 12 months, before getting re-evaluated for assessing the effectiveness of the applied therapies.",[114],"Intrabony Periodontal Defect",[116,117,118],"Periodontal regeneration","Inta-bony defects","Enamel matrix derivatives","2026-04-13",{"date":121,"type":42},"2026-04-16",{"date":123,"type":42},"2023-01-01",{"date":125,"type":21},"2027-06-30",{"name":48,"class":49},{"id":128,"slug":129,"hasResults":11,"nctId":130,"briefTitle":131,"officialTitle":132,"acronym":4,"eligibilityCriteria":133,"healthyVolunteers":106,"sex":134,"minAge":135,"maxAge":136,"enrollmentInfo":137,"targetDuration":4,"studyType":22,"phases":139,"briefSummary":140,"conditions":141,"keywords":143,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":146,"startDateStruct":148,"completionDateStruct":150,"leadSponsor":152,"locationsCount":50},"100571334","mitigating-response-to-stressors-in-pregnant-women-100571334","NCT06718907","Mitigating Response to Stressors in Pregnant Women","Mitigating Response to Stressors in the Pregnant Woman","Inclusion Criteria: in 24 weeks gestation or more\n\n* between 21 and 37 years of age\n\nExclusion Criteria:\n\n* in less than 24 weeks gestation\n* high risk pregnancies","FEMALE","21 Years","37 Years",{"count":138,"type":21},50,[24],"Stress-induced pregnancy complications are significant contributors to preterm labor as well as maternal and perinatal morbidity and mortality. The goals of this study are two folds: first it aims to capture the pregnant woman's journey to seek and receive prenatal care. Second, this study aims to develop models that 1) assess the adverse health and biological effects of social factors on pregnant women who experience repeated or chronic stress, 2) address how stress can be mitigated in pregnant women from different backgrounds who experience high stress.",[142],"Pregnancy",[144],"stressors, chronic stress, pregnancy, stress regulation, stress management","2026-02-24",{"date":147,"type":42},"2026-02-25",{"date":149,"type":42},"2024-12-20",{"date":151,"type":21},"2026-12-31",{"name":48,"class":49},{"id":154,"slug":155,"hasResults":11,"nctId":156,"briefTitle":157,"officialTitle":158,"acronym":159,"eligibilityCriteria":160,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":161,"enrollmentInfo":162,"targetDuration":4,"studyType":22,"phases":164,"briefSummary":165,"conditions":166,"keywords":168,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":145,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":179},"100560774","efficacy-of-a-breathwork-practice-sky-on-well-being-of-individuals-with-parkinsons-disease-ipd-and-care-partners-100560774","NCT06581523","Efficacy of a Breathwork Practice (SKY) on Well-Being of Individuals With Parkinson's Disease (iPD) and Care Partners","A Feasibility and Efficacy Study of a Breathwork and Meditation Intervention (SKY Breath) on the Psychophysiological Well-Being of Individuals With Parkinson's Disease (iPD) and Their Care Partners","SKYforiPD","Inclusion Criteria:\n\nIndividuals with Parkinson's Disease (iPD) Inclusion Criteria: An individual with a formal diagnosis of iPD that:\n\n* are in stages 1, 2, or 3\n* are at least 18 years of age\n* are no older than 75 years of age\n* can understand, read, write and speak English at a 5th grade level\n* that have access to zoom sessions online via laptop, ipad or other mobile device\n* are able to secure reliable transportation for themselves.\n\nCare Partner of the individuals with Parkinson's Disease (iPD) Inclusion Criteria: Individuals who:\n\n* are a care partner for an individual with Parkinson's Disease but are not paid professional givers of care\n* are at least 18 years of age or older\n* are able to secure reliable transportation for themselves and for the Individual with Parkinson's Disease\n* can understand, read, write and speak English at a 5th grade level\n* has access to zoom sessions online via laptop, iPad or other mobile device.\n\nExclusion Criteria:\n\nIndividuals with Parkinson's Disease (iPD): An individual who\n\n* has been diagnosed with Parkinson's Disease that is in stages 4 or 5 of the disease\n* is younger that age 18 or older than age 75\n* has bipolar disorder\n* has seizure disorder\n* has schizophrenia or schizoaffective disorder\n* has active substance use\n* has uncontrolled hypertension\n* has cognitive impairment that prevents them from memorizing (remembering) the steps to complete the daily breath and meditation practice or completing the survey instruments, or has difficulty following sequential directions of the breathing practice\n* cannot understand, read, write and speak English at a 5th grade level\n* does not have access to zoom sessions online via laptop, iPad or other mobile device\n* can not secure transportation to the site for the training of the breath and meditation practice\n\nCare partner of the Individuals with Parkinson's Disease (iPD): Individuals who:\n\n* are paid professional givers of care\n* are under the age of 18\n* an emancipated minor\n* have bipolar disorder\n* have seizure disorder\n* have schizophrenia or schizoaffective disorder\n* have active substance use\n* have uncontrolled hypertension\n* are not able to secure reliable transportation for themselves\n* cannot understand, read, write and speak English at a 5th grade level\n* does not have access to access to zoom sessions online via laptop, iPad or other mobile device.","75 Years",{"count":163,"type":21},40,[24],"The goal of this feasibility study and clinical trial is to learn if an evidenced-based breathwork and meditation intervention (SKY Breath) will improve the mental and physical well-being of individuals with Parkinson's Disease (iPD) in stages 1, 2, and 3, under the age of 75 and their care partners. The main questions it aims to answer are:\n\n* Objective 1: Can the SKY Breath practice be designed and implemented to specifically cater to the unique needs of individuals with Parkinson's Disease and their care partners.\n* Objective 2: Will the SKY Breath practice decrease stress levels (a contributor to increasing PD symptoms) for individuals with Parkinson\\'s Disease (iPD) and their care partners as measured through self-reported surveys to improve overall well-being and quality of life.\n* Objective 3: Will the SKY Breath practice in part alleviate the emotional stress and physical burden experienced by care partners of PD patients, promoting their resilience and well-being.\n\nParticipants will be asked to learn the SKY Breath and Meditation practice over the course of 4 days (2.25 hours each morning), practice SKY every day for 4 weeks and keep a log of time spent doing SKY. The participants will complete a series of surveys before learning the practice and then after at weeks 1, 4 and 8. The series of surveys will take about 20 minutes.",[167],"Parkinson's Disease",[167,169,170,171],"Sudarshan Kriya Yoga","SKY Breath and Meditation","Care Partner of Individuals with Parkinson's Disease",{"date":173,"type":42},"2026-02-27",{"date":175,"type":42},"2024-10-19",{"date":177,"type":21},"2026-04-30",{"name":48,"class":49},3,{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":185,"acronym":4,"eligibilityCriteria":186,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":187,"targetDuration":189,"studyType":190,"phases":4,"briefSummary":191,"conditions":192,"keywords":194,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":198,"lastUpdatePostDateStruct":199,"startDateStruct":200,"completionDateStruct":202,"leadSponsor":204,"locationsCount":50},"100619185","digital-speech-markers-for-monitoring-als-in-spanish-speakers-100619185","NCT07341334","Digital Speech Markers for Monitoring ALS in Spanish Speakers","Developing Digital Speech Biomarkers of Bulbar Disease Decline in Spanish-Speaking Persons With Amyotrophic Lateral Sclerosis","Inclusion Criteria:\n\n* diagnosis of definite ALS\n* monolingual or first language Spanish speaker\n* literate in Spanish\n* ALS Functional Rating Scale speech score of ≧2\n\nExclusion Criteria:\n\n* no diagnosis of concomitant respiratory disease such as COPD, emphysema, or current TOB use.",{"count":188,"type":21},35,"4 Years","OBSERVATIONAL","The goal of this observational study is to learn how speech and breathing change over time in Spanish-speaking individuals with amyotrophic lateral sclerosis (ALS) compared to age- and gender-matched individuals without ALS.\n\nThe main questions it aims to answer are:\n\nCan speech and breathing measures collected through a smartphone application serve as reliable digital biomarkers to track bulbar disease decline in Spanish-speaking people with ALS?\n\nHow do these measures differ between individuals with ALS and those without ALS?\n\nResearchers will compare Spanish-speaking participants with ALS to age- and gender-matched healthy controls to see if specific speech and breathing features can identify or predict bulbar decline.\n\nParticipants will:\n\nUse a Spanish-language smartphone application to record speech and breathing tasks over time.\n\nComplete assessments of speech, breathing, and functional abilities (e.g., ALS Functional Rating Scale).\n\nProvide data that will be compared to caregiver reports and clinical outcomes to validate new digital biomarkers.",[31,193,33],"Lou Gehrig's Disease",[195,196,197,33],"speech biomarkers","amyotrophic lateral sclerosis","Lou Gehrig's disease","2026-02-23",{"date":147,"type":42},{"date":201,"type":21},"2026-04",{"date":203,"type":21},"2029-12",{"name":48,"class":49},{"id":206,"slug":207,"hasResults":11,"nctId":208,"briefTitle":209,"officialTitle":210,"acronym":4,"eligibilityCriteria":211,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":57,"enrollmentInfo":212,"targetDuration":4,"studyType":22,"phases":214,"briefSummary":215,"conditions":216,"keywords":218,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":223,"lastUpdatePostDateStruct":224,"startDateStruct":226,"completionDateStruct":228,"leadSponsor":230,"locationsCount":50},"100509473","combined-respiratory-training-in-persons-with-als-100509473","NCT05913882","Combined Respiratory Training in Persons With ALS","Combined Respiratory Training to Improve Pulmonary and Cough Function in Persons With ALS","Inclusion Criteria:\n\n1. A diagnosis of probable or definite ALS in accordance with the Revisited El-Escorial Criteria.\n2. Disease duration from symptom onset of ≤ 2 years,\n3. Lung volume recruitment and expiratory muscle strength training naïve,\n4. Reduced peak cough flow (% predicted for age and gender).\n\nExclusion Criteria:\n\n1. History of stroke, head and neck cancer or other concomitant disorder that might contribute to dysphagia or respiratory impairment.\n2. Use of prescription cough assist or non-invasive volume ventilation devices.\n3. Enrollment in another research investigation that might impact cough or respiratory function.\n4. Diagnosis of frontotemporal dementia or advanced cognitive impairment.\n5. Tracheostomy placement\u002FUse of invasive mechanical ventilation.\n6. Contraindications for respiratory training (i.e., history of pneumothorax, severe chronic obstructive pulmonary disease).",{"count":213,"type":21},34,[24],"The goal of this interventional trial is to learn about lung volume recruitment (LVR) and expiratory muscle strength training (EMST) in a total of up to 39 patients diagnosed with ALS. The following aims will be addressed:\n\n1. Determine the impact of combined LVR and EMST on cough strength and respiratory function in individuals with ALS.\n2. Determine the impact of combined LVR and EMST on patient-reported dyspnea and bulbar impairment.\n3. Describe the effect of combined LVR and EMST on patient- and caregiver reported burden and quality of life.",[33,217,63],"Respiratory Insufficiency",[219,220,221,222],"Breathing","Swallowing","Exercise","Bulbar","2025-12-16",{"date":225,"type":42},"2025-12-23",{"date":227,"type":42},"2023-08-22",{"date":229,"type":21},"2026-09-30",{"name":48,"class":49},{"id":232,"slug":233,"hasResults":11,"nctId":234,"briefTitle":235,"officialTitle":236,"acronym":4,"eligibilityCriteria":237,"healthyVolunteers":106,"sex":17,"minAge":4,"maxAge":4,"enrollmentInfo":238,"targetDuration":4,"studyType":22,"phases":240,"briefSummary":241,"conditions":242,"keywords":244,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":253,"lastUpdatePostDateStruct":254,"startDateStruct":255,"completionDateStruct":257,"leadSponsor":259,"locationsCount":50},"100479437","establishing-new-treatment-approaches-for-amblyopia-perceptual-learning-and-video-games-100479437","NCT05522972","Establishing New Treatment Approaches for Amblyopia: Perceptual Learning and Video Games","Improving Normal and Amblyopic Vision With Video Games and Perceptual Learning","Inclusion Criteria:\n\n* adults and children with normal vision or amblyopia\n* amblyopia: interocular VA difference of 0.1 logMAR or more\n\nExclusion Criteria:\n\n* any ocular pathological conditions, nystagmus",{"count":239,"type":21},180,[24],"Amblyopia, a developmental abnormality that impairs spatial vision, is a major cause of vision loss, resulting in reduced visual acuity and reduced sensitivity to contrast. This study uses psychophysical measures to study neural plasticity in both adults and children with amblyopia.",[243],"Amblyopia",[245,246,247,248,249,250,251,252],"perceptual learning","video games","visual plasticity","amblyopia treatment","pathophysiology of amblyopia","vision training","stereoacuity","strabismus","2025-12-08",{"date":223,"type":42},{"date":256,"type":42},"2022-09-13",{"date":258,"type":21},"2029-08-31",{"name":48,"class":49},{"id":261,"slug":262,"hasResults":11,"nctId":263,"briefTitle":264,"officialTitle":265,"acronym":266,"eligibilityCriteria":267,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":268,"targetDuration":4,"studyType":22,"phases":270,"briefSummary":271,"conditions":272,"keywords":278,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":284,"lastUpdatePostDateStruct":285,"startDateStruct":287,"completionDateStruct":289,"leadSponsor":291,"locationsCount":50},"100566232","the-student-wellness-and-emotional-growth-resiliency-swag-r-program-100566232","NCT06652503","The Student Wellness and Emotional Growth Resiliency (SWAG-R) Program","The Student Wellness and Emotional Growth Resiliency (SWAG-R) Program: A 6-week Coaching Program Designed For NSU Undergraduate Students to Decrease Anxiety, Depression, and Stress and Improve Mental Health, Quality of Life, and Resiliency","SWAG-R","Inclusion Criteria:\n\n* Currently matriculating NSU undergraduate students (ages 18+)\n\nExclusion Criteria:\n\n* Students who are not current NSU undergrads, participants aged 17 and younger, students who are currently enrolled in psychotherapy or mental health services, or students with acute mental health needs (e.g., psychosis, active alcohol or substance use problems, suicidality)",{"count":269,"type":21},160,[24],"The purpose of this research study is to provide a free 6-week, online psychological coaching program to NSU undergraduate students to help with anxiety, depression, and stress, while improving quality of life and healthy coping skills.",[273,274,275,276,277],"Anxiety","Depression","Stress","Wellbeing","Quality of Life",[279,280,281,282,283],"anxiety","depression","stress","wellbeing","quality of life","2025-12-05",{"date":286,"type":42},"2025-12-12",{"date":288,"type":42},"2025-01-13",{"date":290,"type":21},"2026-09",{"name":48,"class":49},{"id":293,"slug":294,"hasResults":11,"nctId":295,"briefTitle":296,"officialTitle":296,"acronym":4,"eligibilityCriteria":297,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":298,"targetDuration":4,"studyType":22,"phases":300,"briefSummary":301,"conditions":302,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":306,"lastUpdatePostDateStruct":307,"startDateStruct":309,"completionDateStruct":311,"leadSponsor":312,"locationsCount":50},"100537281","mix-of-demineralized-freeze-dried-bone-allograft-and-deproteinized-bovine-bone-mineral-a-possible-solution-for-alveolar-ridge-preservation-100537281","NCT06275789","Mix of Demineralized Freeze-Dried Bone Allograft and Deproteinized Bovine Bone Mineral: a Possible Solution for Alveolar Ridge Preservation?","Inclusion Criteria:\n\n* Patients in good health\n* Require the extraction of at least one premolar or molar with future implant placement\n* Sufficient keratinized gingiva (equal or more than 2mm prior to extraction),\n* No more than 3mm of buccal bone loss\n* Flapless extraction possible\n* Full mouth plaque index of less than 25%\n\nExclusion Criteria:\n\n* Nicotine consumption equivalent to or more than 10 cigarettes per day\n* Electronic cigarette usage\n* A history of irradiation of head and neck area\n* Immunodeficiency disease\n* Uncontrolled systemic health problems (hypertension crisis 180\u002F120, hyperthyroidism, diabetes with HbA1c over 7, recent history of stroke, cancer) History of medications that affect bone remodeling process (bisphosphonates, RANK-L inhibitors)\n* Previous adverse reaction to the biomaterials used\n* Pregnancy\u002Flactation, or those who are trying to become pregnant.\n* Active uncontrolled or untreated periodontal disease\n* Periapical lesions greater than 1 cm and soft tissue pathology",{"count":299,"type":21},30,[24],"The purpose of the study is to compare a new grafting material for alveolar ridge preservation to a commonly used and well studied material. Alveolar ridge dimensions as well as histology will be compared.",[303,304,305],"Alveolar Ridge Preservation","Dental Extraction","Bone Graft","2025-09-05",{"date":308,"type":42},"2025-09-12",{"date":310,"type":42},"2024-01-26",{"date":70,"type":21},{"name":48,"class":49},{"id":314,"slug":315,"hasResults":11,"nctId":316,"briefTitle":317,"officialTitle":317,"acronym":4,"eligibilityCriteria":318,"healthyVolunteers":106,"sex":17,"minAge":319,"maxAge":320,"enrollmentInfo":321,"targetDuration":4,"studyType":22,"phases":322,"briefSummary":323,"conditions":324,"keywords":329,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":333,"lastUpdatePostDateStruct":334,"startDateStruct":336,"completionDateStruct":338,"leadSponsor":340,"locationsCount":50},"100221201","a-more-engaging-visual-field-test-to-increase-use-and-reliability-in-pediatrics-100221201","NCT02157025","A More Engaging Visual Field Test to Increase Use and Reliability in Pediatrics","Inclusion Criteria:\n\n* Ages 5-8\n* Seen previously in the clinics at Nova Southeastern University's The Eye Care Institute with a diagnosis for glaucoma suspect or optic nerve abnormalities\n* Able and willing to complete VF testing at 2 study visits about a week apart\n* Provide informed consent\n\nExclusion Criteria:\n\n* History of having previously completed a VF test using Humphrey static perimetry\n* Inability to understand study or communicate responses (cognitive impairment)\n* Unable to understand, read and speak English fluently","5 Years","8 Years",{"count":83,"type":21},[24],"The majority of young children do not think that visual field (VF) testing of peripheral vision is similar to a game; therefore, it is not surprising that they have difficulty maintaining attention during VF testing and thus the test reliability suffers as a consequence. Poor VF reliability has been a longstanding, major issue since it leads to an increased number of tests and\u002For longer duration of time needed to determine when there are true vision losses. Providers are less likely to obtain VF tests in children since the results are of doubtful value and challenging to interpret when they are inconsistent. Effectively this means that children with untreated, slowly progressive eye diseases may go undiagnosed and incur greater visual losses. The investigators aim to create a prototype device that the investigators hypothesize will make VF testing more engaging for young children, thus increasing their attention and consistency of their responses to the test stimuli, which in turn should improve VF reliability. The components include a microdisplay video screen (1.5\" diameter) as the fixation target (instead of the standard LED light) displaying video clips of popular cartoon characters, and audio clips of impersonated cartoon character voices presented by the test operator to provide instructional feedback based on the child's performance during testing. Improved VF reliability from the investigators intervention would translate to improved diagnosis and care for young childrens' peripheral vision loss through widespread implementation of the investigators innovative, affordable and readily adoptable system at eye care providers' offices.",[325,326,327,328],"Glaucoma, Suspect","Optic Nerve Hypoplasia and Abnormalities of the Central Nervous System","Congenital Coloboma of the Optic Nerve","Optic Nerve Head Pits, Bilateral Congenital",[330,331,332],"Humphrey visual fields","perimetry","pediatrics","2025-09-03",{"date":335,"type":42},"2025-09-10",{"date":337,"type":42},"2015-02",{"date":339,"type":21},"2027-12",{"name":48,"class":49},{"id":342,"slug":343,"hasResults":11,"nctId":344,"briefTitle":345,"officialTitle":346,"acronym":4,"eligibilityCriteria":347,"healthyVolunteers":106,"sex":17,"minAge":348,"maxAge":349,"enrollmentInfo":350,"targetDuration":4,"studyType":22,"phases":351,"briefSummary":352,"conditions":353,"keywords":355,"overallStatus":65,"whyStopped":4,"lastUpdateSubmitDate":364,"lastUpdatePostDateStruct":365,"startDateStruct":366,"completionDateStruct":368,"leadSponsor":370,"locationsCount":4},"100604559","adolescent-suicide-loss-survivors-grief-intervention-group-100604559","NCT07151092","Adolescent Suicide Loss Survivors Grief Intervention Group","Exploring Experiences of Adolescent Suicide Loss Survivors After Participating in a Grief Intervention Group","Inclusion Criteria:\n\n* \\- Adolescents aged 13-17 years.\n* Survivor of suicide loss.\n* Permission from parent or guardian.\n\nExclusion Criteria:\n\n* Adolescents who have not experienced the loss of a loved one to suicide.","13 Years","17 Years",{"count":83,"type":21},[24],"This study will provide evidence-based recommendations for designing interventions tailored to adolescents dealing with suicide loss. By exploring how these young people experience and make meaning of their grief, the study will contribute to the development of best practices for mental health professionals and educators working with suicide loss survivors. This study will provide evidence-based recommendations for designing interventions tailored to adolescents dealing with suicide loss. By exploring how these young people experience and make meaning of their grief, the study will contribute to the development of best practices for mental health professionals and educators working with suicide loss survivors.\n\nThis study will enhance scientific understanding by examining how adolescents experience grief after suicide loss and identifying which components of bereavement interventions are most effective for this age group. It will improve societal welfare by informing the development of targeted, evidence-based support programs that address the unique mental health needs of bereaved adolescents. Long-term, the findings may reduce the risk of complicated grief and suicidality, support emotional resilience, and guide best practices in schools, clinics, and community settings for supporting youth after traumatic loss.",[354],"Grief",[356,357,358,359,360,361,362,363],"Suicide Loss","Stigmatized Grief","Bereavement","Traumatic grief","adolescent grief group","coping","continuing bonds","hope","2025-08-27",{"date":333,"type":42},{"date":367,"type":21},"2025-09-01",{"date":369,"type":21},"2026-03",{"name":48,"class":49},{"id":372,"slug":373,"hasResults":11,"nctId":374,"briefTitle":375,"officialTitle":376,"acronym":377,"eligibilityCriteria":378,"healthyVolunteers":106,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":379,"targetDuration":4,"studyType":22,"phases":381,"briefSummary":382,"conditions":383,"keywords":385,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":393,"lastUpdatePostDateStruct":394,"startDateStruct":396,"completionDateStruct":398,"leadSponsor":400,"locationsCount":50},"100493057","investigating-cardiac-health-of-adults-with-trauma-100493057","NCT05700201","Investigating Cardiac Health of Adults With Trauma","The Effects of a Cognitive Behavioral Healthy Lifestyle Intervention for Cardiovascular Risk Reduction in Posttraumatic Stress Disorder","I - CHAT","Inclusion Criteria:\n\n* PTSD symptoms\n* overweight OR less than 30 min. of moderate physical activity 5 times per week\n\nExclusion Criteria:\n\n* cannot exercise at a low-moderate level (walking)",{"count":380,"type":21},216,[24],"This project examines the impact of a healthy lifestyle intervention, specifically designed for adults with posttraumatic stress and identified cardiovascular risks.",[384],"Posttraumatic Stress Disorder",[386,387,388,389,390,391,392],"Posttraumatic Stress","Cardiovascular","Health","Intervention","PTSD","Lifestyle","Behavior","2025-07-24",{"date":395,"type":42},"2025-07-29",{"date":397,"type":42},"2023-04-21",{"date":399,"type":21},"2026-08-31",{"name":48,"class":49},{"id":402,"slug":403,"hasResults":11,"nctId":404,"briefTitle":405,"officialTitle":406,"acronym":407,"eligibilityCriteria":408,"healthyVolunteers":11,"sex":17,"minAge":409,"maxAge":410,"enrollmentInfo":411,"targetDuration":4,"studyType":22,"phases":413,"briefSummary":415,"conditions":416,"keywords":418,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":424,"startDateStruct":426,"completionDateStruct":428,"leadSponsor":429,"locationsCount":430},"100438322","early-phase-1-gwictic-nac-mechanistic-study-in-gulf-war-veterans-100438322","NCT04987775","GWICTIC: NAC Mechanistic Study in Gulf War Veterans","Mechanisms of Oxidative Stress During N-Acetyl Cysteine (NAC) Supplementation in Veterans With Gulf War Illness (GWI)","NAC","Inclusion Criteria:\n\n* 47 to 70 years\n* Served in the Gulf War Theater for any period between August 1990 and July 1991.\n* Meets modified Kansas case definition criteria for Gulf War Illness. The modified Kansas definition includes the following:\n\n  1. Allowance of normal illness of aging, such as hypertension and diabetes, if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.\n  2. Allowance of stable comorbid conditions such as Post Traumatic Stress Disorder (PTSD), Major Depressive Disorder (MDD), and mild Traumatic Brain Injury (mTBI) that have not required hospitalization in the 2 years prior to recruitment. Severe TBI is excluded.\n* Able to provide written consent to the study\n* Agrees to participate in follow-up visits.\n\nExclusion Criteria:\n\n* Self-report of current treated or untreated major depression with psychotic or melancholic features (as determined by self-report and Hamilton Depression Inventory (Ham-D)), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or a history of central nervous system (CNS) disorders that may affect cognitive function (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease), or alcoholism or drug abuse\n* Severe claustrophobia or serious difficulty being in an MRI scanner or other enclosed space (MRS substudy only)\n* Presence of ferrous implanted medical devices or metal fragments or objects that are embedded under the skin (MRS substudy only)\n* Current heavy alcohol or tobacco use (self-report). Alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day.\n* Chronic active infections such as HIV, Hepatitis B Virus (HBV), and Hepatitis C Virus (HCV) (self-report or antibody titer)\n* Renal disease (self-report or laboratory results: renal insufficiency with serum creatinine \\> 2.0 mg\u002FdL)\n* Liver disease (self-report or laboratory results: hepatic insufficiency (bilirubin \\>2.5mg\u002FdL or transaminases \\> 3 times the upper limits of normal)\n* Uncontrolled diabetes (HgbA1c \\> 7.5) without adequate medical care. Individuals with HgbA1c \\> 7.5 will be reviewed and judged by the PI or delegate; if potential participant has adequate medical care to manage diabetes, enrollment is allowed; otherwise HgbA1c \\> 7.5 is exclusionary\n* Diagnosed vascular disease (including congestive heart failure)\n* Diagnosed bleeding disorders or use of blood-thinning medications\n* Receipt of stavudine or didanosine for more than 7 days within 30 days prior to screening\n* Currently have exclusionary diagnoses that could reasonably explain the symptoms of their fatiguing illness and their severity\n* Are scheduled for a surgery during the period of study participation or had surgery within 6 weeks prior to screening\n* Pregnant (women only)\n\nProhibited Concomitant or Prior Therapies\n\n* Currently on dialysis\n* Previous or current receipt of any antiviral medication, such as pegylated interferon, ribavirin, entecavir, tenofovir, or didanosine for more than 7 days within 30 days prior to screening\n* Participating in another interventional (including social-behavioral therapy) clinical trial of an investigational therapy within 6 weeks prior to consent, or planning to participate in another interventional clinical trial of an investigational therapy during the course of this study\n* Any herbal medicine within 30 days prior to consent and screening blood draw","47 Years","70 Years",{"count":412,"type":21},170,[414],"EARLY_PHASE1","This mechanistic study will test if NAC affects chronic oxidative stress and depletion of antioxidants in GWI participants. Blood specimen collection and neuroimaging will be used to determine whether NAC affects serum glutathione (GSH) concentration and oxidative stress in the CNS when compared to placebo.",[417],"Gulf War Syndrome",[419,420,421,422],"CNS Recovery","N-Acetyl Cysteine (NAC)","Gulf War Illness","Placebo","2025-07-02",{"date":425,"type":42},"2025-07-08",{"date":427,"type":42},"2023-11-30",{"date":201,"type":21},{"name":48,"class":49},7,{"id":432,"slug":433,"hasResults":11,"nctId":434,"briefTitle":435,"officialTitle":436,"acronym":4,"eligibilityCriteria":437,"healthyVolunteers":11,"sex":17,"minAge":438,"maxAge":439,"enrollmentInfo":440,"targetDuration":4,"studyType":22,"phases":441,"briefSummary":442,"conditions":443,"keywords":444,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":423,"lastUpdatePostDateStruct":447,"startDateStruct":449,"completionDateStruct":451,"leadSponsor":452,"locationsCount":50},"100433685","phase-2-study-of-bacopa-in-gulf-war-illness-patients-100433685","NCT04927338","Study of Bacopa in Gulf War Illness Patients","Phase II, Placebo-controlled Study of BacoMind® Bacopa Monnieri Standardized Extract in Gulf War Illness","Inclusion Criteria:\n\n1. Born in years 1942 to1978\n2. Served in the Gulf War theater for any period between August 1990 and July 1991\n3. Meets modified Kansas case definition criteria and CDC case definition for Gulf War Illness (GWI). The modified Kansas definition, which includes the CDC criteria includes:\n\n   1. Allowance for normal illnesses of aging, such as hypertension and diabetes if the conditions are treated and are in demonstrable stable and normal ranges at the time of screening and assessment.\n   2. Allowance of stable comorbid conditions such as post-traumatic stress disorder (PTSD), major depressive disorder (MDD), and traumatic brain injury (TBI) that have not required hospitalization in the 5 years prior to recruitment. Severe TBI is excluded.\n4. Able to consent to the study\n5. Participants of childbearing potential must practice effective contraception during the study so that, in the opinion of the Investigator, they will be compliant with birth control measures during the study.\n6. Agrees to participate in follow-up visits.\n\nExclusion Criteria:\n\n1. They are scheduled for a surgery during the period of study participation, had minor surgery within 3 months prior to screening, or had major surgery within 6 months prior to screening,\n2. Self-report of current untreated major depression with psychotic or melancholic features (as determined by self-report), schizophrenia, bipolar disorder, delusional disorders, dementias of any type, or substance abuse during the last two years (excluding cannabis products),\n3. Any serious allergic disease (self-report), possibly resulting in anaphylaxis, such as food\u002Fdrug allergies, including allergic asthma, or allergy to any ingredient of the active product or placebo, including allergies to FD\\&C Yellow No. 5 (tartrazine),\n4. Renal disease (self-report; laboratory results: renal insufficiency with serum creatinine \\> 2.0 mg\u002FdL or eGFR \\\u003C 44; or currently on renal dialysis),\n5. Hepatic insufficiency (bilirubin \\>2.5mg\u002FdL or transaminases \\>3x the upper limit of normal (ULN)). Participants with Gilberts syndrome are eligible for the study if other liver function tests are normal, regardless of bilirubin level,\n6. Pregnancy (premenopausal female participants),\n7. Current heavy alcohol or tobacco use (self-report). Heavy use is defined as alcohol consumption not to exceed approximately 15 drinks per week (with a drink defined as 12 oz beer, 5 oz wine, or 1.5 oz distilled spirits) and tobacco use not to exceed 20 cigarettes (or equivalent) per day.\n8. Current exclusionary diagnosis that could reasonably explain the symptoms of their fatiguing illness and their severity, using the exclusion criteria best described in the Ambiguities in case definition paper for Chronic Fatigue Syndrome (CFS), as described in detail in Reeves et al., 2003, which clarifies exclusionary conditions. Specifically, the exclusionary diagnoses that are not otherwise listed above comprise:\n\n   * organ failure (e.g., emphysema, cirrhosis, cardiac failure, chronic renal failure)\n   * chronic infections (e.g., AIDS, hepatitis B or C) or inflammatory bowel disease (IBD) (via self report)\n   * major neurologic diseases that could cause fatigue or neurologic deficits such as (e.g., epilepsy, stroke, brain tumor, multiple sclerosis, Parkinson's Disease, Alzheimer's disease) or history of CNS demyelinating disease (e.g., multiple sclerosis, neuromyelitis optica spectrum disorder) (Self report),\n   * cancer or cancer treatment (e.g., chemotherapy, radiation of brain), or current use of biologic modifiers that could affect immune function (e.g., Etanercept, Rituximab) (self-report)\n   * untreated primary sleep disorders (e.g., sleep apnea, narcolepsy)\n   * uncontrolled diabetes (HgbA1c \\> 7)\n9. Temporary conditions discovered at screening for which participants may be rescreened 6 weeks after resolution of condition.\n\n   * Temporary effects of medications\n   * Temporary sleep deprivation\n   * Untreated hypothyroidism\u002Fhyperthyroidism, hypothyroidism\u002Fhyperthyroidism that has been inadequately controlled during the last 3 months, or free T4 level not within normal limit\n   * Active infection\n10. Participating in another interventional clinical trial of an investigational therapy (including social-behavioral therapy) within 6 weeks prior to consent to participate in this study, or planning to participate in another interventional clinical trial of an investigational therapy during this study,\n11. Use of Bacopa within 6 weeks prior to the enrollment in this study,\n12. Diagnosed bleeding disorder or current use of anticoagulants and\u002For antiplatelets, except for low dose nonsteroidal anti-inflammatories (NSAIDS).","46 Years","78 Years",{"count":412,"type":21},[111],"Gulf War Illness is a condition that affects multiple major organ systems, resulting in a diverse array of symptoms that include debilitating fatigue, memory and cognition difficulties, headaches, sleep disturbances, gastrointestinal problems, skin rashes, and musculoskeletal\u002Fjoint pain. This phase II, double masked, randomized, placebo-controlled, two-arm study will evaluate cognitive function as evidence of efficacy of the nutraceutical intervention, Bacopa, on central nervous system symptom management of Gulf War Illness, along with assessments of safety of the intervention.",[421],[445,421,446],"Veterans","Nutraceutical",{"date":448,"type":42},"2025-07-04",{"date":450,"type":42},"2022-12-01",{"date":201,"type":21},{"name":48,"class":49},{"id":454,"slug":455,"hasResults":11,"nctId":456,"briefTitle":457,"officialTitle":457,"acronym":4,"eligibilityCriteria":458,"healthyVolunteers":11,"sex":17,"minAge":459,"maxAge":410,"enrollmentInfo":460,"targetDuration":4,"studyType":22,"phases":462,"briefSummary":463,"conditions":464,"keywords":4,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":467,"lastUpdatePostDateStruct":468,"startDateStruct":470,"completionDateStruct":472,"leadSponsor":473,"locationsCount":50},"100532304","phase-2-the-use-of-directed-probiotics-in-mecfs-myalgic-encephalomyelitischronic-fatigue-syndrome-100532304","NCT06211062","The Use of Directed Probiotics in ME\u002FCFS: Myalgic Encephalomyelitis\u002FChronic Fatigue Syndrome","Inclusion Criteria: eligible if all of the following apply:\n\n* Meets IOM ME\u002FCFS case definition criteria,\n* Co-morbid IBS: meets RomeIV criteria for alternating or diarrhea-predominant IBS as reported during screening (technically diagnosed by a physician),\n* Able to provide consent to study,\n* Patients of childbearing potential must practice effective contraception during the study and be willing to continue contraception for at least six months after the intervention,\n* agrees to participate in online surveys and follow-up visits.\n\nExclusion Criteria: ineligible if any of the following apply:\n\n* Probiotics in the past eight weeks,\n* Antibiotics in the past eight weeks,\n* Pregnancy or lactating women,\n* Medical conditions including short bowel syndrome, celiac disease, biliary disease, pancreatitis, inflammatory bowel disease (Crohn's disease, ulcerative colitis), severe cardiovascular, neurological condition, or liver failure,\n* Gastrointestinal surgery within six months of study entry,\n* History of psychiatric disorder, alcohol or illicit drug abuse.","45 Years",{"count":461,"type":21},100,[111],"This clinical study aims to evaluate the use of i3.1 probiotic in participants who meet the Institute of Medicine (Canadian Consensus Criteria) case definition for ME\u002FCFS and who may or may not be diagnosed with irritable bowel syndrome (IBS). The main questions it aims to answer are:\n\n* how effective is the usage of the i3.1 probiotic to reduce gastrointestinal (GI) inflammation and normalize the GI and systemic\u002Fbrain interface?\n* how well is it working on IBS severity? The study sample is 100 male and female participants aged 45 to 70 years with ME\u002FCFS (per the Canadian Consensus Criteria); one-half of the participants will have co-morbid IBS (per Rome IV criteria). Participants will receive an i3.1 or a placebo and be assessed at baseline, at eight weeks, and at 12 weeks (four weeks post-treatment completion).",[465,466],"ME\u002FCFS","IBS - Irritable Bowel Syndrome","2025-03-03",{"date":469,"type":42},"2025-03-04",{"date":471,"type":42},"2022-12-20",{"date":145,"type":21},{"name":48,"class":49},{"id":475,"slug":476,"hasResults":11,"nctId":477,"briefTitle":478,"officialTitle":478,"acronym":479,"eligibilityCriteria":480,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":481,"targetDuration":4,"studyType":190,"phases":4,"briefSummary":483,"conditions":484,"keywords":487,"overallStatus":38,"whyStopped":4,"lastUpdateSubmitDate":489,"lastUpdatePostDateStruct":490,"startDateStruct":492,"completionDateStruct":494,"leadSponsor":496,"locationsCount":497},"100557269","substance-use-treatment-and-its-role-in-supporting-social-cognition-100557269","NCT06535919","Substance Use Treatment and Its Role in Supporting Social Cognition","SUE","Inclusion Criteria:\n\n* Meet criteria for a substance Use Disorder, receiving treatment at Recovery Unplugged Addiction Treatment Center, at least 18 years of age.\n\nExclusion Criteria:\n\n* Neurological disorder, severe cognitive impairment, comorbid thought disorder such as schizophrenia, failure to complete detox period,",{"count":482,"type":21},108,"This study aims to assess changes in empathy levels before and after residential treatment among individuals with substance use disorders.",[485,486],"Substance Use","Empathy",[488],"substance use, empathy","2024-11-24",{"date":491,"type":42},"2024-11-27",{"date":493,"type":42},"2024-10-22",{"date":495,"type":21},"2026-01",{"name":48,"class":49},2,""]